Also considered
18 papers judged, 3 emailed · Read the digest →
Comprehensive narrative review of esophageal cancer epidemiology, risk factors, and clinical management, published in NEJM. Provides an authoritative state-of-the-art overview relevant to oncologists managing esophageal adenocarcinoma and squamous cell carcinoma.
Phase 1 dose-escalation trial of the novel dual-state KRAS G12D inhibitor GFH375 in heavily pretreated pancreatic, lung, and colorectal cancers with KRASG12D mutations, published in Nature Medicine. Establishes tolerability and a recommended phase 2 dose, supporting further development of this new targeted approach for a historically undruggable mutation.
NCCN Guidelines Insights update on esophageal and esophagogastric junction cancers, published in JNCCN, providing current recommendations for advanced disease including evolving first-line immunotherapy options for squamous cell carcinoma.
Single-institution retrospective analysis of MSI-H/dMMR gastric and GEJ adenocarcinoma patients treated with immunotherapy, published in JCO Precision Oncology. Identifies clinical benefit patterns and molecular correlates that may help predict durable immunotherapy response in this subgroup.
Single-arm phase 1/2 trial in previously treated metastatic KRAS G12D-mutant pancreatic cancer, published in Cancer Cell. A chemotherapy-free KRAS G12D inhibitor plus PD-L1 blockade combination showed encouraging, durable responses in this refractory population, warranting further study.
Comprehensive narrative review of current therapeutic approaches across gastric cancer stages, published in CA Cancer J Clin. Summarizes evolving standards including perioperative immunotherapy, claudin 18.2-targeted therapy, and antibody-drug conjugates, informing overall management strategy.
Large retrospective difference-in-differences cohort study using the National Cancer Database examining Medicaid expansion and colorectal cancer survival, published in JAMA Network Open. Finds expansion associated with lower mortality, informing policy and access discussions relevant to equitable cancer care delivery.
Single-arm phase 2 trial (PEGASUS) in resected high-risk stage II/III colon cancer, published in Nature Cancer, testing a ctDNA-guided adaptive strategy to escalate or de-escalate adjuvant chemotherapy. Primary endpoint was not met, but the approach showed reduced neurotoxicity versus historical controls, offering exploratory support for biomarker-guided de-escalation strategies.
Translational biomarker study with an exploratory cohort and validation in the NEOLAP trial cohort of advanced pancreatic cancer patients, published in Eur J Cancer. Circulating bacterial DNA dynamics during chemotherapy tracked with outcomes differently by regimen (FOLFIRINOX vs gemcitabine/nab-paclitaxel), suggesting a potential blood-based tool to guide treatment monitoring and regimen selection.
Narrative review/perspective on pancreatic ductal adenocarcinoma biology and resistance mechanisms, published in Cancer Cell. Proposes a conceptual framework for precision interception and future therapeutic strategies rather than reporting new clinical data.
Prospective international biomarker study developing a blood-based microRNA assay combined with CA19-9 for early detection of pancreatic ductal adenocarcinoma, published in Nature Medicine. Shows promising sensitivity for early-stage disease and potential for monitoring recurrence, though it addresses screening/detection rather than treatment selection.
Prespecified secondary quality-of-life analysis from the phase II VOLFI trial in untreated RAS wild-type metastatic colorectal cancer, published in European Journal of Cancer. Shows adding panitumumab to FOLFOXIRI does not meaningfully worsen overall quality of life despite added skin toxicity, supporting its use as a first-line option.
Single-arm multicenter phase 2 trial in previously untreated advanced pancreatic cancer, published in Eur J Cancer, testing a gemcitabine/nab-paclitaxel/S-1 triplet regimen. Shows promising response and conversion-to-surgery rates, suggesting a potential new option pending randomized confirmation.
Target-trial-emulation cohort study using Korean national claims data, published in JAMA Network Open, examining whether starting a statin after colorectal cancer treatment is associated with lower cancer-specific and all-cause mortality. Suggests a possible survival benefit from statin initiation but remains observational and hypothesis-generating rather than practice-changing.
Post-hoc pooled subgroup analysis of the GRECCAR4 and PRODIGE23 randomized trials examining whether adjuvant chemotherapy adds benefit after total neoadjuvant therapy in locally advanced rectal cancer, published in European Journal of Cancer. Suggests adjuvant chemotherapy benefit seen after chemoradiotherapy alone may not extend to patients who already received FOLFIRINOX-based TNT, informing decisions about omitting adjuvant chemotherapy after TNT.
Preclinical translational study developing an optimized L1CAM-targeted CAR-T construct tested in patient-derived xenograft models of ovarian and gastric cancer, published in J Immunother Cancer. Provides early proof-of-concept for a novel CAR-T design but no clinical trial data in patients yet.
Retrospective multi-institutional cohort study characterizing cancer phenotypes associated with a CDKN2A germline variant (I49T) in individuals of Mexican ancestry, published in JCO Precision Oncology. Findings inform genetic counseling and risk assessment for melanoma and pancreatic cancer in variant carriers but do not address treatment selection.
Single-arm phase 2 exploratory study in resectable esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy plus chemoradiotherapy, published in Cancer Imaging, evaluating 18F-FDG PET/CT parameters to predict pathologic complete response and survival. Small study suggesting lymph node SUVmax has diagnostic value, though primary tumor metabolic parameters did not predict pCR, offering modest guidance for response assessment.